AR080871A1 - Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa - Google Patents

Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa

Info

Publication number
AR080871A1
AR080871A1 ARP110101191A ARP110101191A AR080871A1 AR 080871 A1 AR080871 A1 AR 080871A1 AR P110101191 A ARP110101191 A AR P110101191A AR P110101191 A ARP110101191 A AR P110101191A AR 080871 A1 AR080871 A1 AR 080871A1
Authority
AR
Argentina
Prior art keywords
pyridins
inhibitors
activity
replaced
thyrosine kinase
Prior art date
Application number
ARP110101191A
Other languages
English (en)
Spanish (es)
Original Assignee
Otsuka Pharma Co Ltd
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Methylgene Inc filed Critical Otsuka Pharma Co Ltd
Publication of AR080871A1 publication Critical patent/AR080871A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP110101191A 2010-04-16 2011-04-08 Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa AR080871A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16

Publications (1)

Publication Number Publication Date
AR080871A1 true AR080871A1 (es) 2012-05-16

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110101191A AR080871A1 (es) 2010-04-16 2011-04-08 Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
ARP110101195A AR080875A1 (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110101195A AR080875A1 (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa

Country Status (19)

Country Link
US (3) US8455484B2 (enExample)
EP (2) EP2563794A4 (enExample)
JP (2) JP2013523846A (enExample)
KR (2) KR20130100234A (enExample)
CN (2) CN103025740B (enExample)
AR (2) AR080871A1 (enExample)
AU (2) AU2011241420B2 (enExample)
CA (2) CA2796008A1 (enExample)
CO (2) CO6630193A2 (enExample)
EA (2) EA201291055A1 (enExample)
MX (2) MX2012012032A (enExample)
MY (1) MY157319A (enExample)
NZ (2) NZ602948A (enExample)
PH (2) PH12012502073A1 (enExample)
SG (2) SG184882A1 (enExample)
TW (2) TW201204735A (enExample)
UA (1) UA108878C2 (enExample)
WO (2) WO2011127567A1 (enExample)
ZA (2) ZA201207482B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2635131T3 (es) * 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
BRPI0923670A2 (pt) * 2008-03-05 2013-07-30 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase e seu uso, bem como composiÇço compreendendo os mesmos
MY157319A (en) * 2010-04-16 2016-05-31 Methylgene Inc Inhibitors of protein tyrosine kinase activity
US20130090327A1 (en) * 2011-09-30 2013-04-11 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
EP2791108B1 (en) 2011-12-15 2016-07-27 Pfizer Limited Sulfonamide derivatives
WO2016040554A1 (en) 2014-09-10 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
WO2006010264A1 (en) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1904504B1 (en) * 2005-05-20 2014-03-19 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
ES2635131T3 (es) * 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
BRPI0923670A2 (pt) * 2008-03-05 2013-07-30 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase e seu uso, bem como composiÇço compreendendo os mesmos
MY157319A (en) * 2010-04-16 2016-05-31 Methylgene Inc Inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
EA201291052A1 (ru) 2013-04-30
EA201291055A1 (ru) 2013-09-30
AR080875A1 (es) 2012-05-16
EP2563794A1 (en) 2013-03-06
PH12012502073A1 (en) 2013-02-11
ZA201207557B (en) 2013-06-26
JP2013525286A (ja) 2013-06-20
US8455484B2 (en) 2013-06-04
PH12012502070A1 (en) 2015-05-08
ZA201207482B (en) 2013-09-25
CN103025740B (zh) 2015-07-01
EP2563794A4 (en) 2013-12-04
NZ602954A (en) 2014-11-28
NZ602948A (en) 2014-09-26
UA108878C2 (ru) 2015-06-25
MX2012012032A (es) 2012-12-17
US20140315801A1 (en) 2014-10-23
TW201204735A (en) 2012-02-01
CO6630193A2 (es) 2013-03-01
WO2011127565A1 (en) 2011-10-20
US8906852B2 (en) 2014-12-09
CO6640224A2 (es) 2013-03-22
US20110257100A1 (en) 2011-10-20
CN102947315A (zh) 2013-02-27
MY157319A (en) 2016-05-31
SG184883A1 (en) 2012-11-29
EP2563795A4 (en) 2013-10-23
AU2011241422A1 (en) 2012-11-01
TW201204734A (en) 2012-02-01
KR20130058006A (ko) 2013-06-03
AU2011241420B2 (en) 2015-04-16
CN103025740A (zh) 2013-04-03
MX2012012031A (es) 2012-12-17
WO2011127567A1 (en) 2011-10-20
SG184882A1 (en) 2012-11-29
JP2013523846A (ja) 2013-06-17
CA2796008A1 (en) 2011-10-20
KR20130100234A (ko) 2013-09-10
AU2011241422B2 (en) 2015-05-07
CA2796054A1 (en) 2011-10-20
EP2563795A1 (en) 2013-03-06
US20110257175A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
MX381849B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
MX382991B (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
UY37900A (es) Nuevos derivados de rapamicina
MX394360B (es) Inhibidores de jak2 y alk2 y metodos para su uso.
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
MX380928B (es) Inhibidores de kras g12c.
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201001331A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR
MX386542B (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
PH12016502252A1 (en) Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile
PH12015502036A1 (en) Inhibitors of the kynurenine pathway
PE20151501A1 (es) Inhibidores de prmt5 y sus usos
BR112014018355A8 (pt) Composto inibidor de quinase reguladora de sinal de apoptose, composição farmacêutica compreendendo o referido composto, uso e compostos intermediários do mesmo
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
ECSP10010415A (es) Compuestos novedosos que son inhibidores de erk
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы

Legal Events

Date Code Title Description
FB Suspension of granting procedure